To categorially analyze whether the observed changes of AD-like pathology in APP/PS1 mice from Study 1 were primarily driven by the gut-induced changes through CRL treatment; fecal samples of all groups of Study 1 were collected from treatment week 5 to 8. This evidence concerns the gene APP and Alzheimer disease.